The critical role of Remote Sensing in the post-damage assessment of IANOS.The unprecedented heavy rainfall on 18-19 September 2020 over the Greek territory as caused by the Mediterranean Cyclone "Ianos", resulted in the occurrence of extensive flooding in rural and urban areas in the wider region of Thessaly.

New Spin-off Company founded by FORTH for the production of reflection-free glass that improves the quality of consumer electronics displaysA new spin-off company under the name “Biomimetic” was created leveraging patented technology developed at the Institute of Electronic Structure and Laser (IESL, www.iesl.forth.gr) of the Foundation for Research and Technology-Hellas (www.forth.gr). The company was founded by the Research Director Dr. Emmanuel Stratakis, together with FORTH research personnel Dr. Evangelos Skoulas, Mr. Andreas Lemonis, Mr. Antonis Papadopoulos and Mr. Alexandros Mimidis, as co-founders. The company raised 900.000€ seed funding by Big Pi Ventures (https://bigpi.vc/), one of the funds of EquiFund supported by the European Investment Fund (EIF). It is the second spin-off company of IESL that is financed by Big Pi within the last six months.

Biomimetic Omnidirectional Antireflective Glass improves the quality of electronics displaysΑ novel biomimetic method for the realization of omnidirectional transparent antireflective glass was developed by researchers at the Institute of Electronic Structure and Laser (IESL) of the Foundation for Research and Technology – Hellas (FORTH).

Novel method for COVID-19 diagnosis developed at FORTH receives funding for immediate market releaseBiosensors lab of FORTH(http://biosensorslab.biology.uoc.gr/) has developed a novel molecular diagnostic method for the detection of nucleic acids at the point-of-care. The method exploits a newly designed portable 3D-printed device and a smartphone to perform isothermal amplification and real-time quantitative colorimetric detection of the target analyte. The simplicity of the methodology, rapid analysis time (<30 min) and affordable cost make it ideal for non-trained users at the point-of-need and in both the developed and resource limited countries. Clinical validation of the device with patients’ samples, for infectious diseases (COVID-19) and cancer-mutations (BRAF V600E) detection, demonstrated excellent performance compared to standard methods.